Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adele Stewart has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Glebov-Mccloud

    Department of Neuroscience and Pharmacology, The Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA 52242

    1 shared publication
  • Hadley Edwards

    Department of Chemistry and Biochemistry, Florida Atlantic University, Jupiter, 33458, FL, USA

    1 shared publication
  • J Bernholtz

    Department of Neuroscience and Pharmacology, The Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA 52242

    1 shared publication
  • J Yang

    Department of Neuroscience and Pharmacology, The Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA 52242

    1 shared publication
  • Jacob Bernholtz

    Department of Neuroscience and Pharmacology, Carver College of Medicine, University of Iowa, Iowa City, 52242, IA, USA

    1 shared publication
  • Jg Koland

    Department of Neuroscience and Pharmacology, The Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA 52242

    1 shared publication

Latest Publications

  • Open Access

    Molecular cloning of a novel, nervous system-specific RGS6 isoform lacking canonical G protein regulatory effects and with dominant negative actions

    by Ke Ahlers-Dannen, J Yang, J Bernholtz, Alexander Glebov-Mccloud, Stefan Strack, Jg Koland, Ra Fisher, A Stewart

    Regulator of G protein Signaling 6 (RGS6), heavily implicated in neurological and neuropsychiatric disorders, is enriched in mouse and human brain. Our initial cloning effort identified 36 RGS6 mRNAs in human brain. However, we recently identified an additional RGS6 protein isoform that is larger (∼69kDa) than the ubiquitously expressed ∼56kDa RGS6L(+GGL) isoforms. Notably, this isoform, named “RGS6B” for “brain-specific”, is selectively expressed in the nervous system of mice and humans. Here, we report the cloning of a new RGS6-encoding mRNA, which resembles the RGS6Lα1(+GGL) transcript identified in our initial cloning effort but includes a highly conserved novel exon (Alternative 3, A3) that alters the reading frame of terminal exon α resulting in an extension of the protein C-terminus. When expressed in cells, RGS6LA3α1(+GGL) co-migrates with RGS6B, and, importantly, interfering RNA targeting exon A3 results in selective depletion of RGS6B in isolated primary cortical astrocytes. RGS6B is capable of stabilizing RGS6 binding partners R7BP and Gβ 5 and, in fact, exhibits an increased protein half-life relative to RGS6L. Both RGS6L and RGS6B are downregulated in human gliomas and share the ability to kill U87MG glioblastoma cells when overexpressed indicating conservation of non-canonical cytotoxic activity between RGS6L and RGS6B species. However, RGS6B lacks the ability to counteract Gα i/o -dependent suppression of cAMP signaling, indicating a lack of functional GTPase activating protein (GAP) activity. Instead, RGS6B functions in a dominant negative manner to block Gα i/o regulation by RGS6L. RGSB is the first identified RGS protein member that functions to promote, rather than inhibit, G protein signaling. The discovery of the molecular identity of RGS6B will now allow for delineation of unique functions for RGS6 protein isoforms in both physiological and pathophysiological brain states.

  • Open Access

    Consideration of sex as a biological variable over the history of the 5xFAD Alzheimer’s Disease mouse model

    by Julia I. Neuharth, K. Stephanie Hernandez, Jacob Bernholtz, Hadley Edwards, Adele Stewart

    Background: Women are nearly twice as likely to be diagnosed with Alzheimer’s Disease (AD) over their lifetime. However, historically, preclinical studies utilizing AD rodent models to define new therapeutic targets in AD treatment have neglected to consider the confounding influence of subject sex leading to a lack of mechanistic insight into the biological underpinnings of sex bias in AD. Methods: Here, we tracked choice of subject sex over the twenty-year history of the 5xFAD mouse, one of the most frequently cited pre-clinical AD models. We analyzed 1,330 primary research articles indexed on PubMed and recorded information provided regarding subject sex and/or as a rationale for not including datasets separated by sex, if noted. Trends were then plotted as a function of time ending in December 2024. Results: In the last 15 years, the number of published manuscripts on the 5xFAD model omitting information on subject sex has progressively declined. However, the proportion of studies utilizing either males only (29%) or combining data from both sexes (24%) far surpasses studies acknowledging sex as a biological variable (SABV) (< 12%) with no significant changes noted over time. On average, the ratio of male only: female only studies of 5xFAD mice hovered around 2:1. The most frequently cited reason for omitting sex-based analyses was either a lack of sex differences found (29%), accelerated development of plaque burden in 5xFAD females (17%), or the possibility of within- or between-sex variability (15%). Mention of SABV has steadily increased in studies utilizing 5xFAD mice peaking at ~ 30% of manuscripts published in 2024. However, two key confounds in the 5xFAD model, including the potential impact of an estrogen response element (ERE) and parental imprinting in the Thy1 promoter driving transgene expression, have been largely ignored. Conclusions: The 5xFAD model represents a compelling example of how neglecting to recognize the impact of biological sex on neural function can compromise study design and data interpretation. Given sex-dependent Thy1 promoter regulation may skew phenotypic outcomes, investigators should judiciously interpret sex differences observed in any AD mouse utilizing the Thy1 promoter to drive transgene expression.


  • The Ins and Outs of Dopamine Transporter Gene Manipulation: In Vivo Models of DAT Dysfunction

    by Adele Stewart, Randy D. Blakely

    The clinical efficacy of psychostimulant drugs, which target monoamine transporters, in treating attention-deficit/hyperactivity disorders (ADHDs) has stimulated interest on the role of transporter proteins like the dopamine (DA) transporter (DAT) in neurotransmission as well as the potential utility of DAT knockout organisms as models for neuropsychiatric disorders. Indeed, the study of DAT-deficient worms, flies, fish, mice, and rats has revealed a conserved role for DAT in the control of motor behavior as well as repetitive behavior, threat aversion, social behavior, and cognition in mammals. However, the disconnect between phenotypes observed in DAT-deficient model organisms and humans, which exhibit an early-onset syndrome characterized by Parkinsonism/dystonia and premature death, challenges the construct validity of DAT knockout models with respect to modeling neurobehavioral disorders. As an alternate approach, several groups have utilized coding variants in the SLC6A3 gene linked to psychiatric conditions, which display divergent molecular phenotypes. This chapter reviews the development and characterization of models of DAT gene deletion and mutation with a particular emphasis on comparing/contrasting the functional impact of DAT deficiency to DAT dysregulation triggered by neuropsychiatric disorder-linked DAT mutants in vivo. Ultimately, the study of DAT knockout and mutant models has revealed novel functions for DA in the mammalian brain, uncovered a dynamic interplay between the monoaminergic systems, highlighted sex differences in the DA system that determine the behavioral trajectory of DAT deregulation, and allowed for the screening of potential leads for therapeutics to treat disorders linked to aberrant dopaminergic neurotransmission.